Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

Sickle Cell Disease Treatment Commercially Available in Five GCC Countries TORRANCE, Calif., July 13, 2023 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing authorization from the Oman…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.